依达拉奉对急性脑梗死患者神经元特异性烯醇化酶水平的影响

Effect of Edaravone on Serum Neuron Specific Enolase in Acute Cerebral Infarction Patients

目的探讨依达拉奉对急性脑梗死患者神经元特异性烯醇化酶(neuronspecificenolase,NSE)水平的影响。方法选择78例经CT或MRI确诊的发病在48h内的脑梗死患者随机分为依达拉奉组和常规治疗组,分别于治疗前,治疗后第7、14、21天检测两组患者的血清NSE水平,并对两组患者的神经功能缺损程度进行评分。结果治疗前两组患者血清NSE水平间差异无统计学意义(P>0.05);依达拉奉组治疗后第7、14、21天的NSE水平与常规治疗组相应时间的NSE水平比较差异均有统计学意义(P<0.05)。治疗前两组患者神经功能缺损评分比较差异无统计学意义(P>0.05);依达拉奉组治疗后第7、14、21天的神经功能缺损评分与常规治疗组相应时间的评分比较差异均有统计学意义(P<0.05)。结论依达拉奉可以显著降低急性脑梗死患者血清NSE水平,能有效改善急性脑梗死患者的神经功能缺损。

Objective To explore the change of serum neuron specific enolase （NSE） levels in acute cerebral infarction patients and the influence of edaravone on it. Methods Totally 78 patients with acute cerebral infarction （ within 48 hours） diagnosed by CT or MRI were at random divided as edaravone group and routine group. The serum NSE levels of the patients in both groups were measured before treatment, and on the 7th, 14th, 21st day of the treatment. The scores of neurological deficits of the patients in the two groups were before and after treatment also compared. Results The serum NSE levels in the two groups before treatment showed no significantly different （ P 〉 0. 05 ）. The NSE levels on the 7th, 14th, 21 st day of the treatment of the edaravone group were respectively significantly different from those of the routine group （ P 〈 0. 05 ）. There was no significant difference before treatment in score of neurological deficit between the two group （P 〉0. 05）, but there were on the 7th, 14th, 21 st day of the treatment （ P 〈 0.05 ）. Conclusion Edaravone can markedly reduce the serum NSE level and promote the recovery of neurological function in patients with acute cerebral infarction.